Metabolon Closes $8 Million Series B Funding Round
News Jan 19, 2006
Metabolon, Inc. has announced the close of an $8 million Series B funding round. Sevin Rosen Funds led the round with participation from all existing investors including The Aurora Funds and The Trelys Funds. A new investor, Harris & Harris Group, also contributed to the financing.
"Metabolon has come a long way in a short period of time," said Dr. John Ryals, president and CEO of Metabolon.
"Our metabolomics technology is proving to have applications in many areas of pharmaceutical drug discovery and development."
"These funds will allow Metabolon to make substantial progress toward our commercialization goals, and we are delighted to have Harris & Harris Group join our current investors."
"Sevin Rosen Funds looks forward to continuing its work with Metabolon to further the field of metabolomics," said John Oxaal, general partner with Sevin Rosen Funds.
"With Metabolon's deep understanding of metabolic pathways and its ability to detect the early onset of disease, the company is striving to set new standards for drug therapies."
"The power of Metabolon's technology has exceeded The Aurora Funds' expectations," said Jeff Clark, managing general partner at The Aurora Funds.
"The company remains a leader in shaping the future of this important field." The round is joined by Harris & Harris Group.
"Harris & Harris Group is excited to have the opportunity to join the existing syndicate of investors in providing Metabolon with the resources to continue to pursue its commercial strategy with its validated metabolomics platform," said Doug Jamison, president, COO and CFO of Harris & Harris Group.
We’ve all heard the expression: “what doesn’t kill you makes you stronger.” Now, research suggests why, at a cellular level, this might be true. Brief exposures to stressors can be beneficial by prompting the cell to trigger sustained production of antioxidants, molecules that help get rid of toxic cellular buildup related to normal metabolism.